康惠制药(603139) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥127,367,068.27, representing a year-on-year increase of 2.89%[4] - Total operating revenue for Q1 2024 was CNY 127,367,068.27, an increase of 4.76% compared to CNY 123,792,050.57 in Q1 2023[27] - Net profit for Q1 2024 was a loss of CNY 2,482,990.60, compared to a net profit of CNY 8,281,339.16 in Q1 2023[29] - Total comprehensive income attributable to the parent company was CNY 1,086,299.01, compared to CNY 8,206,330.75 in the same quarter last year[31] - The company reported a total comprehensive loss of CNY 2,482,990.60, contrasting with a total comprehensive income of CNY 8,281,339.16 in Q1 2023[31] Profitability Metrics - The net profit attributable to shareholders decreased by 86.76% to ¥1,086,299.01, primarily due to losses from the subsidiary Shandong Youbang[10] - Basic and diluted earnings per share both decreased by 87.50% to ¥0.01[6] - The company achieved a basic and diluted earnings per share of CNY 0.01, down from CNY 0.08 in Q1 2023[31] - The company had a weighted average return on equity of 0.11%, down by 0.73 percentage points[6] Cash Flow and Liquidity - The net cash flow from operating activities increased significantly by 210.46% to ¥8,521,044.26, attributed to changes in the scope of consolidation[10] - In Q1 2024, the company reported cash inflows from operating activities of CNY 179,435,753.02, an increase of 46.5% compared to CNY 122,414,089.94 in Q1 2023[34] - The net cash flow from operating activities was CNY 8,521,044.26, a significant improvement from a net outflow of CNY 7,714,430.19 in the same period last year[36] - The ending cash and cash equivalents balance was CNY 94,196,181.65, a decrease from CNY 203,126,050.68 at the end of Q1 2023[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,972,578,831.15, a decrease of 3.86% compared to the end of the previous year[6] - The company's total assets decreased to CNY 1,972,578,831.15 as of March 31, 2024, from CNY 2,051,724,232.78 at the end of 2023[21] - Current assets totaled CNY 640,795,173.46, down from CNY 708,224,860.35 at the end of 2023, reflecting a decrease of 9.53%[19] - The company's total liabilities decreased to CNY 955,608,137.38 from CNY 1,031,803,480.93 at the end of 2023, a reduction of 7.37%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,784[12] - The largest shareholder, Shaanxi Kanghui Holdings Co., Ltd., held 36.75% of the shares, with 9,080,000 shares pledged[12] Operating Costs and Expenses - Total operating costs for Q1 2024 were CNY 133,377,175.40, up 12.26% from CNY 118,797,207.65 in Q1 2023[27] - The company reported a significant increase in financial expenses, which rose to CNY 7,147,702.94 from CNY 574,593.18, indicating a substantial rise in interest expenses[29] - Cash outflows from investing activities decreased to CNY 10,167,044.79 from CNY 97,117,806.75 year-over-year, resulting in a net cash inflow of CNY 10,707,367.69[36] Inventory and Borrowings - Inventory increased to CNY 218,394,769.75, up 9.73% from CNY 199,346,171.62 at the end of 2023[19] - Long-term borrowings increased to CNY 301,569,311.50 from CNY 282,049,311.50, an increase of 6.67%[23]